Endevica Bio

About Endevica Bio

Endevica Bio is a clinical-stage biopharmaceutical company concentrating on the development of peptide-based therapeutics. Founded in 2009 by Kenneth Gruber, Ph.D., initially as Tensive Controls, the firm focuses on creating treatments for cachexia, a complex metabolic syndrome associated with chronic diseases like cancer that causes severe weight loss and muscle wasting. Dr. Gruber, who serves as the Chief Scientific Officer, has a background in studying melanocortins dating back to the 1980s and invented the company's core compound between academic positions, which allows Endevica to hold the intellectual property rights outright.

The company's business model is centered on advancing its drug candidates through clinical trials to address unmet medical needs. Its primary financial backing comes from investors such as Centennial Investors and Missouri Technology Corporation, highlighted by a $10 million Series B funding round in January 2023. This capital is allocated to research and development, particularly for its lead drug candidate, TCMCB07. The current CEO and Executive Chairman is Russell Potterfield, an entrepreneur with a background in manufacturing, design, and logistics, who initially joined as an angel investor before taking on a leadership role. Potterfield's journey from investor to CEO was driven by his growing conviction in the company's potential, despite not having a traditional biotech background.

Endevica's core technology involves creating peptide drug candidates designed to cross the blood-brain barrier and act on previously inaccessible G protein-coupled receptors (GPCRs). The lead product, TCMCB07, is a melanocortin-3/4 (MC4R) antagonist peptide aimed at reversing cachexia. This condition affects up to 80% of patients with advanced cancer and is a direct cause of death in a significant percentage of cases. TCMCB07 functions by blocking the effects of hormones that cause a lack of appetite and muscle loss. In April 2025, Endevica announced it had begun dosing patients in a Phase 2 clinical trial for TCMCB07 in individuals with stage 4 metastatic colorectal cancer. In addition to cachexia, the company is exploring other applications of its peptide platform, including weight management. This research led to the development of 710GO, an oral MC4R agonist for obesity, which showed promising weight loss results in non-human primates and was subsequently spun off into a new company, Abisati, in late 2024 to focus exclusively on its development.